| scholarly article | Q13442814 |
| P50 | author | Sarman Singh | Q39771858 |
| P2093 | author name string | A Sharma | |
| S K Sharma | |||
| A Biswas | |||
| S Sinha | |||
| S Vishnubhatla | |||
| T Velpandian | |||
| A Satyaraddi | |||
| A Sirohiwal | |||
| G K Makharia | |||
| P433 | issue | 2 | |
| P921 | main subject | hepatotoxicity | Q1349821 |
| tuberculosis | Q12204 | ||
| P304 | page(s) | 188-95, i-iii | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | International Journal of Tuberculosis and Lung Disease | Q15767020 |
| P1476 | title | Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. | |
| P478 | volume | 18 |
| Q38851516 | Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. |
| Q38741481 | Antibiotic Complications During the Treatment of Mycobacterium ulcerans Disease in Australian Patients |
| Q36082913 | Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment |
| Q38763608 | Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis |
| Q98159525 | Development and Application of a LC-MS/MS Method for Simultaneous Quantification of Four First-Line Antituberculosis Drugs in Human Serum |
| Q35028452 | Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels |
| Q26771997 | Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? |
| Q52707803 | Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. |
| Q93075181 | Mid-upper arm circumference predicts death in adult patients admitted to a TB ward in the Philippines: A prospective cohort study |
| Q38502298 | Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia |
| Q89699857 | Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF) |
| Q28553471 | Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting |
| Q28079207 | Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations |
| Q37425851 | Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis |
| Q91699232 | The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study |
| Q37236043 | Traditional Preparations and Methanol Extracts of Medicinal Plants from Papua New Guinea Exhibit Similar Cytochrome P450 Inhibition |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
Search more.